

INCYTE CORP  
Form 8-K/A  
August 03, 2012

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **August 2, 2012**

**INCYTE CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**0-27488**  
(Commission File Number)

**94-3136539**  
(I.R.S. Employer  
Identification No.)

**Experimental Station  
Route 141 & Henry Clay Road  
Building E336  
Wilmington, DE**  
(Address of principal executive offices)

**19880**  
(Zip Code)

**(302) 498-6700**

(Registrant's telephone number,  
including area code)

N/A

## Edgar Filing: INCYTE CORP - Form 8-K/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.02 Results of Operations and Financial Condition.**

On August 2, 2012, Incyte Corporation (the Company) issued a press release announcing financial results for the second quarter of 2012, which was furnished as an exhibit to the Company's Current Report on Form 8-K dated August 2, 2012. In the press release, the Company incorrectly reported that included in total revenues and net income (loss) for the quarter and six months ended June 30, 2012, was a \$40 million milestone payment received from Lilly for baricitinib (LY3009104). In fact, the \$40 million milestone payment was a European Union regulatory milestone payment received from Novartis for ruxolitinib. The full text of the corrected press release is furnished as Exhibit 99.1 to this Form 8-K/A and replaces and supersedes the previously furnished press release.

**Item 9.01 Financial Statements and Exhibits.**

(d) **Exhibits**

99.1 Corrected press release issued by Incyte Corporation dated August 2, 2012.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 2, 2012

INCYTE CORPORATION

By:

/s/ Eric H. Siegel  
Eric H. Siegel  
Executive Vice President and  
General Counsel